RUFINAMIDE
Manufacturer: Aurobindo Pharma Limited
Score: 142.0
Rufinamide is an antiepileptic medication used for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults. The precise mechanism of action is unknown, but it is believed to modulate the activity of sodium channels. Rufinamide is available in film-coated tablets and should be given with food. The recommended starting daily dose is 10 mg/kg per day in pediatric patients and 400 mg to 800 mg per day in adults, with gradual increases until a maximum dose of 45 mg/kg per day or 3200 mg per day is reached. Important safety information includes the risk of suicidal behavior and ideation, central nervous system reactions, QT shortening, and multi-organ hypersensitivity. Contraindications include Familial Short QT syndrome. Special population considerations include use during pregnancy, nursing mothers, pediatric use, and geriatric use.
Risk of suicidal behavior and ideation, central nervous system reactions, QT shortening, and multi-organ hypersensitivity
Increase by 10 mg/kg increments every other day to maximum dose of 45 mg/kg per day, not to exceed 3200 mg per day, in two divided doses
400 mg to 800 mg per day in two equally divided doses
10 mg/kg per day in two equally divided doses